FDA's "Critical Path" Leads To Pharmaceutical Science Advisory Committee Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
The committee will discuss research opportunities under FDA's "Critical Path" initiative. Other topics for the Oct. 19-20 meeting include manufacturing, the risk-based GMP initiative, parametrics and generic drug equivalence.